11 June 2025 : Clinical Research
Predictive Scoring Model for In-Stent Restenosis Risk in Coronary Artery Disease Patients
Pan Wang ABCDEF 1*, Juan Xu ABCDE 1DOI: 10.12659/MSM.947986
Med Sci Monit 2025; 31:e947986
Table 1 Comparative analysis of risk factors for in-stent restenosis in coronary artery disease patients.
| Variable | Non-ISR group (n=136) | ISR group (n=120) | Statistics (t/χ2/W) | P value |
|---|---|---|---|---|
| Minimum stent diameter (mm) | 2.8±0.3 | 2.8±0.3 | 0.00 | 1 |
| Tandem stenting n (%) | 53 (39%) | 47 (39%) | 0.01 | 0.97 |
| Number of stents n | 2 (1, 3) | 2 (1, 4) | 0.28 | 0.56 |
| eGFR (ml/min/1.73 m) | 87±21 | 85±28 | 0.65 | 0.52 |
| Body weight (kg) | 72±13 | 71±11 | 0.69 | 0.49 |
| Bifurcation stenting n (%) | 9 (7%) | 12 (10%) | 0.97 | 0.33 |
| HDL-C (mmol/L) | 1.14±0.21 | 1.10±0.25 | 1.39 | 0.17 |
| Hypertension n (%) | 113 (83%) | 106 (88%) | 1.42 | 0.23 |
| Creatinine (μmol/L) | 90±26 | 95±30 | 1.43 | 0.15 |
| Total stent length (mm) | 52±27 | 58±33 | 1.6 | 0.11 |
| Male n (%) | 91 (67%) | 89 (74%) | 1.61 | 0.2 |
| Age (years) | 72±10 | 70±9 | 1.67 | 0.1 |
| TG (mmol/L) | 1.5±0.9 | 1.7±1.0 | 1.68 | 0.09 |
| Total bilirubin (μmol/L) | 12±4 | 13±5 | 1.78 | 0.08 |
| Pre-procedural smoking n (%) | 78 (57%) | 80 (67%) | 2.34 | 0.13 |
| Uric acid (μmol/L) | 314 (269, 378) | 346 (284, 429) | 3.98 | <0.01 |
| HbA1c (%) | 6.9±1.1 | 7.5±1.3 | 4.00 | <0.01 |
| LDL-C (mmol/L) | 2.3±0.6 | 2.7±0.8 | 4.56 | <0.001 |
| D-dimer (μg/L) | 0.58 (0.25, 0.93) | 0.88 (0.68, 1.15) | 5.89 | <0.001 |
| Post-procedural smoking n (%) | 25 (18%) | 43 (37%) | 9.95 | <0.01 |
| Family history of CAD n (%) | 33 (24%) | 54 (45%) | 13.05 | <0.001 |
| Diabetes n (%) | 60 (44%) | 80 (67%) | 13.08 | <0.001 |
| BP controlled n (%) | 131 (96%) | 94 (78%) | 19.39 | <0.001 |
| eGFR – estimated glomerular filtration rate; HDL-C – high-density lipoprotein cholesterol; TG – triglycerides; LDL-C – low-density lipoprotein cholesterol; HbA1c – glycated hemoglobin; CAD – coronary artery disease; BP – blood pressure. | ||||